Icariin: A Potential Alternative Against Osteoporosis

Long, Longhai; Wang, Xiaoqiang; Lijun, Yang; Guo, Sheng; Wang, Chenglong; Dai, Wenbin; Lin, Birong; Xie, Mingzhong; Xu, Houping; Li, Sen

doi:10.1177/1934578x221134881

Cited by 3 publications

(3 citation statements)

References 127 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The maturation of osteoblasts and the formation of bones can potentially be improved by ICA, showcasing its potential in treating osteoporosis [ 180 ]. It boosts ALP function and raises the expression of receptor activator of nuclear factor κ-B ligand, resulting in enhanced bone formation.…”

Section: Applications In Bone Tissue Engineeringmentioning

confidence: 99%

Promoting osteogenesis and bone regeneration employing icariin-loaded nanoplatforms

Mohammadzadeh,

Zarei,

Abbasi

et al. 2024

J Biol Eng

View full text Add to dashboard Cite

There is an increasing demand for innovative strategies that effectively promote osteogenesis and enhance bone regeneration. The critical process of bone regeneration involves the transformation of mesenchymal stromal cells into osteoblasts and the subsequent mineralization of the extracellular matrix, making up the complex mechanism of osteogenesis. Icariin’s diverse pharmacological properties, such as anti-inflammatory, anti-oxidant, and osteogenic effects, have attracted considerable attention in biomedical research. Icariin, known for its ability to stimulate bone formation, has been found to encourage the transformation of mesenchymal stromal cells into osteoblasts and improve the subsequent process of mineralization. Several studies have demonstrated the osteogenic effects of icariin, which can be attributed to its hormone-like function. It has been found to induce the expression of BMP-2 and BMP-4 mRNAs in osteoblasts and significantly upregulate Osx at low doses. Additionally, icariin promotes bone formation by stimulating the expression of pre-osteoblastic genes like Osx, RUNX2, and collagen type I. However, icariin needs to be effectively delivered to bone to perform such promising functions.Encapsulating icariin within nanoplatforms holds significant promise for promoting osteogenesis and bone regeneration through a range of intricate biological effects. When encapsulated in nanofibers or nanoparticles, icariin exerts its effects directly at the cellular level. Recalling that inflammation is a critical factor influencing bone regeneration, icariin's anti-inflammatory effects can be harnessed and amplified when encapsulated in nanoplatforms. Also, while cell adhesion and cell migration are pivotal stages of tissue regeneration, icariin-loaded nanoplatforms contribute to these processes by providing a supportive matrix for cellular attachment and movement. This review comprehensively discusses icariin-loaded nanoplatforms used for bone regeneration and osteogenesis, further presenting where the field needs to go before icariin can be used clinically.

show abstract

Section: Applications In Bone Tissue Engineeringmentioning

confidence: 99%

Promoting osteogenesis and bone regeneration employing icariin-loaded nanoplatforms

Mohammadzadeh,

Zarei,

Abbasi

et al. 2024

J Biol Eng

View full text Add to dashboard Cite

show abstract

“…Changes in bone turnover markers and uterine weight were also measured. Phytoestrogens significantly increased both trabecular and/or cortical bone volume in OVX-induced bone loss with no uterotrophic effect in animal models (Inchingolo et al, 2020;Long et al, 2022). Phytoestrogen was also shown to significantly decreased urinary excretion of deoxypyridinoline (DPD), which is one of the bone resorption markers (Li et al, 2021;Song et al, 2016).…”

Section: Phytoestrogens and Bonementioning

confidence: 99%

Overview on postmenopausal osteoporosis and periodontitis: The therapeutic potential of phytoestrogens against alveolar bone loss

et al. 2023

View full text Add to dashboard Cite

Osteoporosis and periodontitis are two major chronic diseases of postmenopausal women. The association between these two diseases are evident through systemic bone loss and alveolar bone loss. Both postmenopausal osteoporosis and periodontitis impose a considerable personal and socioeconomic burden. Biphosphonate and hormone replacement therapy are effective in preventing bone loss in postmenopausal osteoporosis and periodontitis, but they are coupled with severe adverse effects. Phytoestrogens are plant-based estrogen-like compounds, which have been used for the treatment of menopause-related symptoms. In the last decades, numerous preclinical and clinical studies have been carried out to evaluate the therapeutic effects of phytoestrogens including bone health. The aim of this article is to give an overview of the bidirectional interrelationship between postmenopausal osteoporosis and periodontitis, summarize the skeletal effects of phytoestrogens and report the most studied phytoestrogens with promising alveolar bone protective effect in postmenopausal osteoporosis model, with and without experimental periodontitis. To date, there are limited studies on the effects of phytoestrogens on alveolar bone in postmenopausal osteoporosis. Phytoestrogens may have exerted their bone protective effect by inhibiting bone resorption and enhancing bone formation. With the reported findings on the protective effects of phytoestrogens on bone, well-designed trials are needed to better investigate their therapeutic effects. The compilation of outcomes presented in this review may provide an overview of the recent research findings in this field and direct further in vivo and clinical studies in the future.

show abstract

“…Expression of miR214 inhibits bone formation and promotes osteoclast production [ 28 ]. In addition, some traditional Chinese medicines, such as icariin, also have anti-osteoporotic effects [ 29 ]. Figure 1 describes the mechanism of action of different anti-OP drugs, and Table 1 generalizes the anti-OP drugs used in the clinical stage.…”

Section: The Pathophysiology Of Op and Clinical Medicamentsmentioning

confidence: 99%

Drug Delivery and Therapy Strategies for Osteoporosis Intervention

Ma,

Zeng,

Yang

et al. 2023

Molecules

View full text Add to dashboard Cite

With the advent of the aging society, osteoporosis (OP) risk increases yearly. Currently, the clinical usage of anti-OP drugs is challenged by recurrent side effects and poor patient compliance, regardless of oral, intravenous, or subcutaneous administration. Properly using a drug delivery system or formulation strategy can achieve targeted drug delivery to the bone, diminish side effects, improve bioavailability, and prolong the in vivo residence time, thus effectively curing osteoporosis. This review expounds on the pathogenesis of OP and the clinical medicaments used for OP intervention, proposes the design approach for anti-OP drug delivery, emphatically discusses emerging novel anti-OP drug delivery systems, and enumerates anti-OP preparations under clinical investigation. Our findings may contribute to engineering anti-OP drug delivery and OP-targeting therapy.

show abstract

Icariin: A Potential Alternative Against Osteoporosis

Cited by 3 publications

References 127 publications

Promoting osteogenesis and bone regeneration employing icariin-loaded nanoplatforms

Promoting osteogenesis and bone regeneration employing icariin-loaded nanoplatforms

Overview on postmenopausal osteoporosis and periodontitis: The therapeutic potential of phytoestrogens against alveolar bone loss

Drug Delivery and Therapy Strategies for Osteoporosis Intervention

Contact Info

Product

Resources

About